| HOME >> BIOLOGY >> TECHNOLOGY |
CriticalPoint, LLC, in partnership with Baxa Corporation, announces the availability of a free online reference tool for understanding state laws
and regulations related to sterile compounding and USP compliance.
ENGLEWOOD, Colo., July 30 /PRNewswire/ -- Baxa Corporation announces the availability of a comprehensive new reference tool for understanding the compliance requirements for sterile compounding and USP < 797 > compliance. The interactive reference map was developed by ClinicalIQ, LLC, CriticalPoint, LLC and the National Association of Boards of Pharmacy(R). The tool offers state-specific guidelines on professional licensing and training requirements, State Board of Pharmacy harmonization with USP < 797 > guidelines and sterile compounding laws.
According to Peter Cantor, CriticalPoint development lead, "This project was developed as a response to the need among pharmacy managers and other healthcare providers to understand the legal and professional requirements for sterile compounding and licensure. As a provider of continuing education and USP < 797 > compliance training for pharmacies, we wanted to take this opportunity to give something back to the compounding community. The research provides an important tool for our customers in understanding the laws and regulations that govern their work." The complimentary reference tool is available online and is maintained by Cantor and other CriticalPoint staff members.
Baxa Corporation markets the CriticalPoint compliance training modules
as part of its Productivity and Compliance Tools (PACT) product line, which
includes the Skills Training, Academics and Resources (STAR) Center
classroom-based training for USP < 797 > compliance and aseptic
compounding. The CriticalPoint program offers an interactive, Web-based
training solution for sterile compounding education and regulatory
compliance. The online crosswalk tool complements the CriticalPoint
training by providing up-to-date
'/>"/>
| SOURCE Baxa Corporation Copyright©2008 PR Newswire. All rights reserved |